Shining a Light on Lung Cancer: The Promise of Abenacianine

ONCOLife presents an exclusive interview with John Santini, CEO of Vergent Bioscience. In this session, we explore how intraoperative molecular imaging with abenacianine for injection (VGT-309) is transforming lung cancer surgery. We explore the VISUALIZE Phase 2B study, where abenacianine helped detect tumors missed by standard methods in 45% of cases, enabling more complete and precise resections. You can follow this interview on LinkedIn by this link:>>>

John Santini shares insights on how this innovation is advancing minimally invasive and robotic-assisted surgery, and what’s next as Vergent prepares for its pivotal Phase 3 trial.

Some of the key topics in this interview include:

✔️ How abenacianine improves tumor visualization in real time
✔️ The clinical impact of identifying hidden or incomplete tumor margins
✔️ Integration of this imaging agent into existing surgical workflows
✔️ What the Phase 2B results mean for the future of oncologic surgery
✔️ Plans for Phase 3 and broader applications beyond lung cancer